Paper36919124
The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
Alorjani M and 7 others. Med Arch, 2023. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study. Papers, record 36919124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36919124
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Prostatic Neoplasms | Major topic |
| Male | |
| Humans | |
| Germ-Line Mutation | |
| Checkpoint Kinase 1 | |
| Prevalence | |
| Retrospective Studies | |
| Checkpoint Kinase 2 |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12533788 | Mutations in CHEK2 associated with prostate cancer risk. | Am J Hum Genet | 2003 | https://conductscience.org/library/papers/12533788 | PubMed |
| 2 | 25583358 | CHEK2 mutations and the risk of papillary thyroid cancer. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25583358 | PubMed |
| 3 | 15131084 | Collaboration of Brca1 and Chk2 in tumorigenesis. | Genes Dev | 2004 | https://conductscience.org/library/papers/15131084 | PubMed |
| 4 | 30614821 | PTEN Loss in a Prostate Cancer Cohort From Jordan. | Appl Immunohistochem Mol Morphol | 2020 | https://conductscience.org/library/papers/30614821 | PubMed |
| 5 | 11746983 | Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. | Genes Chromosomes Cancer | 2002 | https://conductscience.org/library/papers/11746983 | PubMed |
| 6 | 27425814 | High frequency of gene mutations in metastatic prostate cancer. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27425814 | PubMed |
| 7 | 18162465 | ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. | J Biol Chem | 2008 | https://conductscience.org/library/papers/18162465 | PubMed |
| 8 | 15539958 | Chk1 is essential for tumor cell viability following activation of the replication checkpoint. | Cell Cycle | 2005 | https://conductscience.org/library/papers/15539958 | PubMed |
| 9 | 28067867 | Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories. | Nat Commun | 2017 | https://conductscience.org/library/papers/28067867 | PubMed |
| 10 | 23296741 | The risk of gastric cancer in carriers of CHEK2 mutations. | Fam Cancer | 2013 | https://conductscience.org/library/papers/23296741 | PubMed |
| 11 | 14678969 | The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. | Cancer Res | 2003 | https://conductscience.org/library/papers/14678969 | PubMed |
| 12 | 10617473 | Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. | Science | 1999 | https://conductscience.org/library/papers/10617473 | PubMed |
| 13 | 23157136 | [Epidemiology and risk factors of the prostate cancer]. | Pol Merkur Lekarski | 2012 | https://conductscience.org/library/papers/23157136 | PubMed |
| 14 | 19230643 | Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. | Curr Opin Cell Biol | 2009 | https://conductscience.org/library/papers/19230643 | PubMed |
| 15 | 9744884 | The Xenopus Chk1 protein kinase mediates a caffeine-sensitive pathway of checkpoint control in cell-free extracts. | J Cell Biol | 1998 | https://conductscience.org/library/papers/9744884 | PubMed |
| 16 | 26629066 | CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/26629066 | PubMed |
| 17 | 14612911 | CHEK2 variants associate with hereditary prostate cancer. | Br J Cancer | 2003 | https://conductscience.org/library/papers/14612911 | PubMed |
| 18 | 16899408 | DNA damage-induced cell death by apoptosis. | Trends Mol Med | 2006 | https://conductscience.org/library/papers/16899408 | PubMed |
| 19 | 20592345 | TP53 gene mutations in prostate cancer progression. | Anticancer Res | 2010 | https://conductscience.org/library/papers/20592345 | PubMed |
| 20 | 10859164 | Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. | Genes Dev | 2000 | https://conductscience.org/library/papers/10859164 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42025253 | Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: implications for a precision treatment approach. | Neoplasia | 2026 | https://conductscience.org/library/papers/42025253 | PubMed |
| 40434671 | FOXM1 Promotes Non-Small Cell Lung Cancer Progression by Increasing CHEK1 Expression. | Curr Med Sci | 2025 | https://conductscience.org/library/papers/40434671 | PubMed |
| 40344565 | Predicting breast cancer prognosis based on a novel pathomics model through CHEK1 expression analysis using machine learning algorithms. | PLoS One | 2025 | https://conductscience.org/library/papers/40344565 | PubMed |
| 40247989 | DEP domain‑containing 1 is a prognostic biomarker associated with the cell cycle in gliomas. | Oncol Lett | 2025 | https://conductscience.org/library/papers/40247989 | PubMed |
| 40116118 | Role of multi‑omics in advancing the understanding and treatment of prostate cancer (Review). | Mol Med Rep | 2025 | https://conductscience.org/library/papers/40116118 | PubMed |
| 39329938 | Novel Mutations in AKT1 Gene in Prostate Cancer Patients in Jordan. | Curr Issues Mol Biol | 2024 | https://conductscience.org/library/papers/39329938 | PubMed |
| 37970346 | Whole Exome Sequencing reveals clinically important pathogenic mutations in DNA repair genes across lung cancer patients. | Am J Cancer Res | 2023 | https://conductscience.org/library/papers/37970346 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRCA1 | 672 | PubTator's text mining | https://conductscience.org/library/genes/672 | NCBI Gene |
| BRCA2 | 675 | PubTator's text mining | https://conductscience.org/library/genes/675 | NCBI Gene |
| CHEK1 | 1111 | PubTator's text mining | https://conductscience.org/library/genes/1111 | NCBI Gene |
| CHEK2 | 11200 | PubTator's text mining | https://conductscience.org/library/genes/11200 | NCBI Gene |
| FOXA1 | 3169 | PubTator's text mining | https://conductscience.org/library/genes/3169 | NCBI Gene |
| KLK3 | 354 | PubTator's text mining | https://conductscience.org/library/genes/354 | NCBI Gene |
| PTEN | 5728 | PubTator's text mining | https://conductscience.org/library/genes/5728 | NCBI Gene |
| SPOP | 8405 | PubTator's text mining | https://conductscience.org/library/genes/8405 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36919124
GET https://conductscience.org/api/papers/v1/36919124/references?page=2